Infectious disease
The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.
Finally, Pfizer has submitted the request to FDA to grant emergency use status to their vaccine for children. Here’s everything you should know about the vaccine.
Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
In a new “Measuring the Return from Pharmaceutical Innovation” report by Deloitte’s Center for Health Solutions, returns from R&D innovation are up by 7% across the industry.
Pfizer announced that Dr. William Pao, M.D., Ph.D., will take on the role of executive vice president and chief development officer as of March 21.
Microbiologics, Inc. commemorated its 50th anniversary in 2021 by playing a key role in helping the world manage the COVID-19 pandemic.
Novavax is finally submitting an Emergency Use Authorization request to the U.S. Food and Drug Administration for its COVID-19 vaccine candidate, NVX-CoV2373, a protein-based vaccine.
WRNMC researchers have found a way to create a vaccine that can recognize multiple spike proteins at once by using ferritin. Here’s more about pan coronavirus vaccine.
News that a subvariant of the Omicron variant has appeared in the U.S. and parts of Europe doesn’t seem like good news. The latest data suggest it’s 1.5 times more transmissible than the original Omicron variant, but not necessarily deadlier.
Clinical trial news definitely picked up this final week of January. Here’s a look.
PRESS RELEASES